Pharmacovigilance databases are important for tracking rare adverse events associated with medications. Approximately 51 new drugs are approved each year by the United States Federal Drug Agency and rare adverse events may be too infrequent to be detected in pre-approval clinical trials, thus the importance of these ongoing pharmacovigilance databases. Using the Federal Drug Agency pharmacovigilance databases, Schifano et al. found trazadone, olanzapine, and tadalafil had a higher risk of causing priapism compared to other medications within this database. We attempted to validate these findings using a large US claims database to assess the frequency of priapism diagnosis within 6 months of prescribing medications identified by Schifano et al. (trazodone, quetiapine, risperidone, olanzapine, aripiprazole, tadalafil, sertraline, sildenafil, methylphenidate, alprostadil, and clozapine). On propensity-matched retrospective cohort analysis with 3.4 million men exposed to the drugs of interest with 3.4 million propensity-matched controls. We find that trazadone and tadalafil were associated with increased risk of priapism – risk ratio [RR] 1.73, 95% Confidence Interval [CI] 1.28–2.34 and (RR: 3.00, 95% CI 2.19–4.11), respectively. Sildenafil was also found to be associated with increased risk of priapism diagnosis (RR: 1.77, 95% CI 1.37–2.29). The antipsychotic quetiapine, a second-generation antipsychotic like olanzapine, had the greatest association with a diagnosis of priapism (RR 3.50, 95% CI 1.93–6.34). Some analyses were unable to be performed, such as for alprostadil and olanzapine, as low number of patients having received a prescription for these medications resulted in a propensity-matched control group that was too small to accurately assess the risk ratio for the incidence of priapism. We confirm the findings of Schifano et al. describing the increased risk of priapism associated with prescriptions of trazadone, tadalafil, sildenafil, and second-generation antipsychotics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The summation data presented in this study are available on request from the corresponding author. The data are not publicly available as data analysis is performed within a subscription model database.
References
Mullard A. 2021 FDA approvals. Nat Rev Drug Disco. 2022;21:83–88.
Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57:970–2.
Schifano N, Capogrosso P, Boeri L, Fallara G, Cakir O, Castiglinone F et al. Medications mostly associated with priapism events: assessment of the 2015-20 Food and Drug 2 Administration (FDA) pharmacovigilance database entries. Int J Impot Res. 2022.
Gogolak VV. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see. Pharmacoepidemiol Drug Saf. 2003;12:249–52.
Bégaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288:1588.
Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225–32.
Salonia A, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Vardi Y, et al. European Association of Urology guidelines on priapism. Eur Urol. 2014;65:480–9.
Author information
Authors and Affiliations
Contributions
Concept and Design: All Authors. Acquisition of Data: TPK. Analysis and Interpretation of Data: All Authors. Drafting of the Manuscript: CA. Critical Revision of the Manuscript: JRK, TPK. Obtaining Funding: None. Supervision: TPK
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Able, C., Kohn, J.R. & Kohn, T.P. Medication-associated priapism events: validation of findings from the FDA pharmacovigilance database using insurance claim database. Int J Impot Res 36, 97–99 (2024). https://doi.org/10.1038/s41443-022-00562-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-022-00562-8